# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
New data published in JACC: Heart Failure demonstrate durable benefits in MLWHF and EQ-5D quality of life measures in heart fai...
Cantor Fitzgerald analyst Ross Osborn initiates coverage on CVRx (NASDAQ:CVRX) with a Overweight rating and announces Price ...
Lake Street analyst Frank Takkinen reiterates CVRx (NASDAQ:CVRX) with a Buy and maintains $12 price target.
New Payment Effective October 1, 2024
Piper Sandler analyst Matt O'Brien maintains CVRx (NASDAQ:CVRX) with a Overweight and lowers the price target from $15 t...
Canaccord Genuity analyst William Plovanic maintains CVRx (NASDAQ:CVRX) with a Buy and raises the price target from $14 to $15.
For the full year of 2024, the Company now expects: Total revenue between $50.0 million and $53.0 million; Gross margin bet...